生酮疗法治疗帕金森病、阿尔茨海默病和轻度认知障碍:一项综合综述

IF 2.7 4区 医学 Q1 NURSING
Susan Price MSN, RN, FNP-BC , Todd M. Ruppar PhD, RN, FAAN
{"title":"生酮疗法治疗帕金森病、阿尔茨海默病和轻度认知障碍:一项综合综述","authors":"Susan Price MSN, RN, FNP-BC ,&nbsp;Todd M. Ruppar PhD, RN, FAAN","doi":"10.1016/j.apnr.2023.151745","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span>Ketogenic therapies have shown benefit for seizure reduction in epilepsy but their impact on other neurologic conditions is less known. In this literature review, the efficacy of ketogenic therapies were assessed in </span>Parkinson's disease<span> (PD), Alzheimer's disease<span> (AD), and mild cognitive impairment (MCI).</span></span></p></div><div><h3>Methods</h3><p>A literature search was conducted using PubMed, Scopus, and Google Scholar focusing on ketogenic therapies in PD, AD, and MCI.</p></div><div><h3>Results</h3><p>A total of 2565 records were identified with a total of 15 studies (3 for PD and 12 for MCI/AD) meeting criteria for analysis. The ketogenic diet<span><span> was used in all the PD studies and did show significant improvement in motor function either through vocal quality, gait, freezing, tremor, and/or balance. A variety of ketogenic therapies were utilized in the MCI and AD groups including a ketogenic diet, low-carbohydrate diet, modified Adkins diet, Mediterranean diet with coconut oil<span> supplementation, a ketogenic diet with a ketogenic medium chain triglyceride (kMCT) supplement, as well as ketogenic supplements including a ketogenic drink with kMCT, oral ketogenic compounds (Axona and AC-1202), and MCT oil or emulsion. The ketogenic diet independently showed a non-significant trend towards improvement in cognition. The Mediterranean diet, modified Adkins diet, and low-carbohydrate diet showed statistically significant improvements in some, although not all, of their cognitive measures. Use of ketogenic supplements, drinks, or compounds showed variable results in the AD and MCI groups. The </span></span>Axona and AC-1202 compounds showed no significant improvement in cognition at the end of their respective 90-day trials. Most MCT supplements did show cognitive improvements, although only after 6 months of adherence. Adherence to the intervention was problematic in most of the diet studies.</span></p></div><div><h3>Conclusion</h3><p>Ketogenic therapies have promise in PD, AD, and MCI for symptom improvement although larger studies are needed to support their implementation in clinical practice.</p></div>","PeriodicalId":50740,"journal":{"name":"Applied Nursing Research","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2023-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ketogenic therapies in Parkinson's disease, Alzheimer's disease, and mild cognitive impairment: An integrative review\",\"authors\":\"Susan Price MSN, RN, FNP-BC ,&nbsp;Todd M. Ruppar PhD, RN, FAAN\",\"doi\":\"10.1016/j.apnr.2023.151745\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p><span>Ketogenic therapies have shown benefit for seizure reduction in epilepsy but their impact on other neurologic conditions is less known. In this literature review, the efficacy of ketogenic therapies were assessed in </span>Parkinson's disease<span> (PD), Alzheimer's disease<span> (AD), and mild cognitive impairment (MCI).</span></span></p></div><div><h3>Methods</h3><p>A literature search was conducted using PubMed, Scopus, and Google Scholar focusing on ketogenic therapies in PD, AD, and MCI.</p></div><div><h3>Results</h3><p>A total of 2565 records were identified with a total of 15 studies (3 for PD and 12 for MCI/AD) meeting criteria for analysis. The ketogenic diet<span><span> was used in all the PD studies and did show significant improvement in motor function either through vocal quality, gait, freezing, tremor, and/or balance. A variety of ketogenic therapies were utilized in the MCI and AD groups including a ketogenic diet, low-carbohydrate diet, modified Adkins diet, Mediterranean diet with coconut oil<span> supplementation, a ketogenic diet with a ketogenic medium chain triglyceride (kMCT) supplement, as well as ketogenic supplements including a ketogenic drink with kMCT, oral ketogenic compounds (Axona and AC-1202), and MCT oil or emulsion. The ketogenic diet independently showed a non-significant trend towards improvement in cognition. The Mediterranean diet, modified Adkins diet, and low-carbohydrate diet showed statistically significant improvements in some, although not all, of their cognitive measures. Use of ketogenic supplements, drinks, or compounds showed variable results in the AD and MCI groups. The </span></span>Axona and AC-1202 compounds showed no significant improvement in cognition at the end of their respective 90-day trials. Most MCT supplements did show cognitive improvements, although only after 6 months of adherence. Adherence to the intervention was problematic in most of the diet studies.</span></p></div><div><h3>Conclusion</h3><p>Ketogenic therapies have promise in PD, AD, and MCI for symptom improvement although larger studies are needed to support their implementation in clinical practice.</p></div>\",\"PeriodicalId\":50740,\"journal\":{\"name\":\"Applied Nursing Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2023-10-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Applied Nursing Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0897189723000794\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"NURSING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied Nursing Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0897189723000794","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NURSING","Score":null,"Total":0}
引用次数: 0

摘要

生酮疗法对减少癫痫发作有好处,但对其他神经系统疾病的影响尚不清楚。在这篇文献综述中,我们评估了生酮疗法在帕金森病(PD)、阿尔茨海默病(AD)和轻度认知障碍(MCI)中的疗效。方法通过PubMed、Scopus和Google Scholar检索PD、AD和MCI的生酮疗法相关文献。结果共获得2565份记录,其中符合分析标准的研究15份(PD 3份,MCI/AD 12份)。在所有PD研究中都使用了生酮饮食,并且通过声音质量,步态,冻结,震颤和/或平衡确实显示出运动功能的显着改善。在MCI和AD组中使用了各种生酮疗法,包括生酮饮食、低碳水化合物饮食、改良阿德金斯饮食、地中海饮食加椰子油补充剂、生酮饮食加生酮中链甘油三酯(kMCT)补充剂,以及生酮补充剂,包括含kMCT的生酮饮料、口服生酮化合物(Axona和AC-1202)和MCT油或乳剂。生酮饮食对认知的改善没有明显的趋势。地中海饮食、改良阿德金斯饮食和低碳水化合物饮食在某些(尽管不是全部)认知测量方面显示出统计学上显著的改善。在AD组和MCI组中,使用生酮补充剂、饮料或化合物显示出不同的结果。Axona和AC-1202化合物在各自90天的试验结束时,对认知能力没有显着改善。大多数MCT补充剂确实显示出认知能力的改善,尽管只是在坚持服用6个月之后。在大多数饮食研究中,坚持干预是有问题的。结论生酮疗法在PD、AD和MCI中有改善症状的希望,尽管需要更大规模的研究来支持其在临床实践中的实施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Ketogenic therapies in Parkinson's disease, Alzheimer's disease, and mild cognitive impairment: An integrative review

Background

Ketogenic therapies have shown benefit for seizure reduction in epilepsy but their impact on other neurologic conditions is less known. In this literature review, the efficacy of ketogenic therapies were assessed in Parkinson's disease (PD), Alzheimer's disease (AD), and mild cognitive impairment (MCI).

Methods

A literature search was conducted using PubMed, Scopus, and Google Scholar focusing on ketogenic therapies in PD, AD, and MCI.

Results

A total of 2565 records were identified with a total of 15 studies (3 for PD and 12 for MCI/AD) meeting criteria for analysis. The ketogenic diet was used in all the PD studies and did show significant improvement in motor function either through vocal quality, gait, freezing, tremor, and/or balance. A variety of ketogenic therapies were utilized in the MCI and AD groups including a ketogenic diet, low-carbohydrate diet, modified Adkins diet, Mediterranean diet with coconut oil supplementation, a ketogenic diet with a ketogenic medium chain triglyceride (kMCT) supplement, as well as ketogenic supplements including a ketogenic drink with kMCT, oral ketogenic compounds (Axona and AC-1202), and MCT oil or emulsion. The ketogenic diet independently showed a non-significant trend towards improvement in cognition. The Mediterranean diet, modified Adkins diet, and low-carbohydrate diet showed statistically significant improvements in some, although not all, of their cognitive measures. Use of ketogenic supplements, drinks, or compounds showed variable results in the AD and MCI groups. The Axona and AC-1202 compounds showed no significant improvement in cognition at the end of their respective 90-day trials. Most MCT supplements did show cognitive improvements, although only after 6 months of adherence. Adherence to the intervention was problematic in most of the diet studies.

Conclusion

Ketogenic therapies have promise in PD, AD, and MCI for symptom improvement although larger studies are needed to support their implementation in clinical practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Applied Nursing Research
Applied Nursing Research 医学-护理
CiteScore
4.50
自引率
0.00%
发文量
65
审稿时长
70 days
期刊介绍: Applied Nursing Research presents original, peer-reviewed research findings clearly and directly for clinical applications in all nursing specialties. Regular features include "Ask the Experts," research briefs, clinical methods, book reviews, news and announcements, and an editorial section. Applied Nursing Research covers such areas as pain management, patient education, discharge planning, nursing diagnosis, job stress in nursing, nursing influence on length of hospital stay, and nurse/physician collaboration.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信